Riccardo Zanni
University of Valencia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Riccardo Zanni.
Current Computer - Aided Drug Design | 2014
Riccardo Zanni; María Gálvez-Llompart; Jorge Gálvez; Ramón García-Domenech
The main purpose of the present review is to summarize the most significant works up to date in the field of multi-target QSAR (mt-QSAR), in order to emphasize the importance that this technique has acquired over the last decade. Unlike traditional QSAR techniques, mt-QSAR permits to calculate the probability of activity of a given compound against different biological or pharmacological targets. In simple terms, a single equation for multiple outputs. To emphasize more the importance of the mt-QSAR in the field of drug discovery, we also present a novel mt-QSAR model, made on purpose by our research group, for the prediction of the susceptibility of Gram + and Gram - anaerobic bacteria.
Expert Opinion on Drug Discovery | 2015
Riccardo Zanni; María Gálvez-Llompart; Ramón García-Domenech; Jorge Gálvez
Introduction: Molecular topology (MT) has emerged in recent years as a powerful approach for the in silico generation of new drugs. In the last decade, its application has become more and more popular among the leading research groups in the field of quantitative structure–activity relationships (QSAR) and drug design. This has, in turn, contributed to the rapid development of new techniques and applications of MT in QSAR studies, as well as the introduction of new topological indices. Areas covered: This review collates the main innovative techniques in the field of MT and provides a description of the novel topological indices recently introduced, through an exhaustive recompilation of the most significant works carried out by the leading research groups in the field of drug design and discovery. The objective is to show the importance of MT methods combined with the effectiveness of the descriptors. Expert opinion: Recent years have witnessed a remarkable rise in QSAR methods based on MT and its application to drug design. New methodologies have been introduced in the area such as QSAR multi-target, Markov networks or perturbation methods. Moreover, novel topological indices, such as Bourgas’ descriptors and other new concepts as the derivative of a graph or cliques capable to distinguish between conformers, have also been introduced. New drugs have also been discovered, including anticonvulsants, anineoplastics, antimalarials or antiallergics, just to name a few. In the authors’ opinion, MT and QSAR have moved from an attractive possibility to representing a foundation stone in the process of drug discovery.
Molecular Diversity | 2015
Ramón García-Domenech; Riccardo Zanni; María Gálvez-Llompart; Jorge Gálvez
Multi-target QSAR is a novel approach that can predict simultaneously the activity of a given chemical compound on different pharmacological targets. In this work, we have used molecular topology and statistical tools such as multilinear regression analysis and artificial neural networks, to achieve a multi-target QSAR model capable to predict the antiprotozoal activity of a group of benzyl phenyl ether diamine derivatives. The activity was related to three parasites with a high prevalence rate in humans: Trypanosoma brucei rhodesiense, Plasmodium falciparum, and Leishmania donovani. The multi-target model showed a high regression coefficient (
Drug Discovery Today: Technologies | 2013
Jorge Gálvez; María Gálvez-Llompart; Riccardo Zanni; Ramón García-Domenech
PLOS ONE | 2015
Riccardo Zanni; María Gálvez-Llompart; Cecilia Morell; Nieves Rodríguez-Henche; Inés Díaz-Laviada; Maria Carmen Recio-Iglesias; Ramón García-Domenech; Jorge Gálvez
{R}^{2} = 0.9644
Expert Opinion on Drug Discovery | 2013
Ramón García-Domenech; María Gálvez-Llompart; Riccardo Zanni; María del Carmen Recio; Jorge Gálvez
Combinatorial Chemistry & High Throughput Screening | 2013
Ramón García-Domenech; Riccardo Zanni; María Gálvez-Llompart; J. Vicente de Julian-Ortiz
R2=0.9644 and
Current Drug Metabolism | 2014
J. Vicente de Julian-Ortiz; Riccardo Zanni; María Gálvez-Llompart; Ramón García-Domenech
Expert Opinion on Drug Discovery | 2013
Jorge Gálvez; María Gálvez-Llompart; Riccardo Zanni; Ramón García-Domenech
{R}^{2} = 0.9235
Molecular Diversity | 2018
Riccardo Zanni; María Gálvez-Llompart; Inma Garcia-Pereira; Jorge Gálvez; Ramón García-Domenech